Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

GHIT Fund Announces New Investments: A Total of 740 Million Yen for Malaria Drugs and Vaccine

GHIT Logo

News provided by

Global Health Innovative Technology (GHIT) Fund

Mar 30, 2022, 22:08 ET

Share this article

Share toX

Share this article

Share toX

TOKYO, March 30, 2022 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total of approximately 740 million yen (US$6.4 million*) to invest in three partnerships to develop new lifesaving tools for malaria.** (Appendix 1 & 2)

Continue Reading
GHIT Charts
GHIT Charts

"We are very pleased to invest in new product development for malaria. Existing innovations alone are not sufficient to combat malaria," said GHIT CEO Osamu Kunii. "Continuous R&D efforts for new innovations are essential for malaria elimination. We hope that these new innovations will be important tools in the malaria elimination strategy and bring greater impact for patients."

Preclinical development of a monoclonal antibody to prevent P. falciparum malaria

GHIT will invest 539 million yen (US$4.7 million) for the development of monoclonal antibodies (mAbs) for malaria prevention.. The project is enabled by access to a panel of potent anti-CSP mAbs, identified from volunteers who were protected against P. falciparum challenge following immunization with RTS,S/AS01 (RTS,S), the world's first malaria vaccine recommended for use in young children living in areas of moderate to high malaria transmission by the World Health Organization (WHO). RTS,S functions primarily by inducing high titer antibodies to the invariant repeat region of the P. falciparum CS protein. Highly potent monoclonal antibodies (mAbs) in protective antisera are likely to be promising tools for malaria intervention.

Development of a Plasmodium vivax multistage vaccine effective both for protection and transmission locking

GHIT will invest 69.8 million yen (US$604K) in the development of a highly effective and durable next-generation multistage/multispecies malaria vaccine that is effective against both pre-erythrocytic stage and sexual-stage P. falciparum and P. vivax parasites.

Hit-to-Lead development of novel Astellas compounds with antimalarial activity

Finally, GHIT will invest 131 million yen (US$1.1 million) in identification of lead compound series with antimalarial activity that has clear potential for further development and progression to lead optimization. Previous project supported by GHIT, four novel hit compounds with antimalarial activity were identified from screening of Astellas's 20,000 compounds. The compounds will be designed to explore both structure activity relationships and scope for structural modification to improve the compound profile such as potency, DMPK, and safety.

As of March 31, there are 61 ongoing projects, including 28 discovery, 21 preclinical and 12 clinical trials, in the GHIT portfolio (Appendix 3). The total amount of investments since 2013 is 27.6 billion yen (US$239 million).

* USD1 =  JPY¥115.59, the approximate exchange rate on February 28, 2022. 
** These awarded projects were selected from a number of proposals to the RFP2021-002 for Target Research Platform, Screening Platform, Hit-to-Lead Platform, and Product Development Platform, which was open for applications from June 2021 to January 2022. The GHIT board conducted in February 2022 approved these new investments.

The GHIT Fund is a Japan-based international public-private partnership fund (PPP) between the Government of Japan, multiple pharmaceutical companies, the Bill & Melinda Gates Foundation, the Wellcome, and the United Nations Development Programme (UNDP). The GHIT Fund invests and manages an R&D portfolio of development partnerships aimed at neglected diseases, such as malaria, tuberculosis and neglected tropical diseases that afflict the world's vulnerable and underserved populations. The GHIT Fund mobilizes the Japanese industry, academia, and research institutes to create new drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical diseases, in collaboration with global partners.

Appendix.1 New Investments

ID/Status

Project Title

Collaboration Partners

Disease/Intervention

Stage

Awarded Amount

G2021-111

New project

Preclinical development of a monoclonal antibody to prevent P. falciparum malaria

Ehime University, Eisai Co., Ltd., GlaxoSmithKline, PATH

Malaria

Drug

Lead Optimization

¥538,661,663

(US$4,660,106)

H2021-201

New project

Hit-to-Lead development of novel Astellas compounds with antimalarial activity

Astellas Pharma Inc., TCG Lifesciences Private Limited. (TCGLS), Medicines for Malaria Venture (MMV)

Malaria

Drug

Lead Identification

¥131,743,584

(US$1,139,749)

T2021-256

New project

Development of a Plasmodium vivax multistage vaccine effective both for protection and transmission blocking 

Hokkaido University, Jichi Medical University, Kanazawa University, Kyoto University, University of Toyama, University of Cambridge, Instituto Leônidas & Maria Deane (ILMD) and The Fundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD)

Malaria
Vaccine

Antigen Identification

¥69,817,000

(US$604,006)

*All amounts are listed at the exchange rate of USD1 = JPY¥115.59, the approximate exchange rate on February 28, 2022.

Appendix.2 Project Details

G2021-111

Project Title

Preclinical development of a monoclonal antibody to prevent P. falciparum malaria

Collaboration Partners

Ehime University, Eisai Co., Ltd., GlaxoSmithKline, PATH

Disease

Malaria

Intervention

Drug

Stage

Lead Optimization

Awarded Amount

¥538,661,663 (US$4,660,106)

Status

New project

Summary

[Project objective]

The objective of this project is to complete preclinical development work to support future IND submission for a proof-of-concept clinical trial including controlled human malaria infection (CHMI). The long-term goal of this project is to secure a WHO policy recommendation and financing for a monoclonal antibody that prevents P. falciparum malaria in young children, and potentially pregnant women, living in areas of seasonal transmission in sub-Saharan Africa. 

1) Manufacture a cell bank for the lead mAb production, and demonstrate the efficacy of the lead mAb in a mouse challenge model

2) Complete process development and manufacture the lead mAb suitable for a GLP toxicology study

3) Complete a pre-IND meeting with the US FDA

4) Complete preliminary Cost-of-Goods (COGs) analysis for anti-malaria infection mAbs, and develop an initial integrated product development and policy plan (iPDPP).

 

[Project design]

The project is built on successful completion of prior work including 1) in vitro and in vivo screening for a lead panel of mAbs; 2) engineering the lead panel mAbs to enhance potency and serum stability, and to minimize development risk identified by in silico analyses; 3) minimizing risk of selected mAbs with cross-reactivity to human tissues by early screening for binding to human tissues and human membrane proteins; 4) confirming in vivo protective efficacy and pharmacokinetics of the selected mAbs in mouse models; 5), initiate cell line development and select one to advance; and 6) established capabilities of mAb production process development, optimization, and production. The proposed work will start with production and release of a pre-master cell bank for production of the mAb of final selection. The manufacture process for the mAb will be developed and optimized to confirm conditions for production of the mAb lot suitable for GLP toxicity studies, and to enable future scale up of production for clinical trial materials. In addition, formulation development will be conducted to enable stability of the mAb at high concentration to accommodate potential subcutaneous injection. The mAb materials produced during process development and the mAb lot for the GLP toxicity studies will be evaluated in mouse challenge model to confirm protective efficacy. A pre-IND meeting will be conducted with the US FDA. We will also conduct IND-enabling GLP-toxicology studies to evaluate repeated dose toxicity and tissue-cross reactivity of the mAb. In parallel, a COGs analysis will be conducted with information on methods of production, product configuration (vial type and size), and a competitive landscape analysis will be conducted with information on mAbs in development for malaria prevention. Finally, an iPDPP will be drafted for alignment among clinical, regulatory, manufacturing, and policy strategies for global health deployment of mAbs and alike.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/201/en

H2021-201

Project Title

Hit-to-Lead development of novel Astellas compounds with antimalarial activity

Collaboration Partners

Astellas Pharma Inc., TCG Lifesciences Private Limited. (TCGLS), Medicines for Malaria Venture (MMV)

Disease

Malaria

Intervention

Drug

Stage

Lead Identification

Awarded Amount

¥131,743,584 (US$1,139,749)

Status

New project

Summary

[Project objective]

The objective of the project is to identify at least 1 novel compound series meeting MMV Early Lead Criteria (1) that has clear potential for further development and progression to Lead Optimization.

 

[Project design]

The project will consist of two phases. The first 6-month phase will involve the synthesis and profiling of small set of compounds designed around each of the four hit compounds identified in the previous project. The compounds will be designed to explore both structure activity relationships (SAR) and scope for structural modification to improve the compound profile (potency, DMPK, safety, etc.). Two series will be selected for Hit-to-Lead studies. The second 18-month phase of the project will involve the optimization of the series (prioritizing the series with the greatest potential) with the goal of identifying a series with a frontrunner compound meeting the MMV Early Lead criteria.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/202/en

T2021-256

Project Title

Development of a Plasmodium vivax multistage vaccine effective both for protection and transmission blocking 

Collaboration Partners

Hokkaido University, Jichi Medical University, Kanazawa University, Kyoto University, University of Toyama, University of Cambridge, Instituto Leônidas & Maria Deane (ILMD) and The Fundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD)

Disease

Malaria

Intervention

Vaccine

Stage

Antigen Identification

Awarded Amount

¥69,817,000 (US$604,006)

Status

New project

Summary

[Project objective]

The project  aim is to develop not only a highly effective and durable multistage vaccine against pre-erythrocytic and sexual stages of P. vivax, but additionally, a bivalent vaccine effective both for P. vivax and P. falciparum.

 

[Project design]

Two viral-vectored vaccines expressing both pre-erythrocytic-stage and sexual-stage antigens of P. vivax will be generated. Protective and transmission blocking (TB) efficacies of the heterologous prime-boost immunization regimen will be assessed by sporozoite challenge and Direct Membrane Feeding Assay (DMFA) in a robust and proven mouse model, and then the regime will be further optimized (e.g., dose, route, interval and outbred mice). Desired protection rate >90%. Surrogate markers responsible for protection will be identified. This will be key to allow efficient and robust measurements of efficacy. Humoral and cellular immune responses induced by the heterologous prime-boost immunization regimen will be assessed. Meanwhile, a bivalent vaccine harboring the genes encoding antigens of both P. vivax and P. falciparum will be generated. In a non-human primate model, in vitro sporozoite neutralizing assay and in vivo sporozoite challenge test of mice passively transferred with immune monkey IgGs will be performed to evaluate its protective efficacy. For evaluation of transmission blocking efficacy, immune monkey sera will be tested by DMFA using blood of vivax patients in Brazil and of falciparum patients in Burkina Faso.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/200/en

*All amounts are listed at the exchange rate of USD1 = JPY¥115.59, the approximate exchange rate on February 28, 2022.

Appendix.3 Investment Overview (As of March 31, 2022)

 1. Investment to date 
Total investments 27.6 billion yen (US$239 million*) 
Total invested projects 114(active projects 61, completed projects 53)

*All amounts are listed at the exchange rate of USD1 = JPY¥115.59, the approximate exchange rate on February 28, 2022.

To know more about GHIT investments, please visit 
Investment Overview: https://www.ghitfund.org/investment/overview/en
Portfolio: https://www.ghitfund.org/investment/portfolio/en
Advancing Portfolio: https://www.ghitfund.org/investment/advancingportfolio/en
Clinical Candidates: https://www.ghitfund.org/investment/clinicalcandidates/en

For more information, contact:
Katy Lenard at +1-301-280-5719 or [email protected] 
Bumpei Tamamura at +81-36441-2032 or [email protected]

SOURCE Global Health Innovative Technology (GHIT) Fund

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.